Communications Biology (Mar 2023)
Protection against Omicron BA.1/BA.2 severe disease 0–7 months after BNT162b2 booster
Abstract
Patient data from the Israeli Ministry of Health demonstrates that a 3rd dose of BNT162b2 is effective in reducing Omicron BA.1/BA.2 severe disease and does not wane over the seven month study period as well as that a fourth dose further improves the protective features of vaccination.